Zhe Jiang Dayang Biotech Group Co., Ltd. Stock

Equities

003017

CNE100004736

Commodity Chemicals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-29 pm EDT 5-day change 1st Jan Change
18.48 CNY +0.71% Intraday chart for Zhe Jiang Dayang Biotech Group Co., Ltd. +13.51% -24.01%
Sales 2021 783M 108M Sales 2022 1.06B 146M Capitalization 1.65B 227M
Net income 2021 70M 9.67M Net income 2022 80M 11.05M EV / Sales 2021 2.91 x
Net cash position 2021 232M 32.03M Net cash position 2022 145M 20.09M EV / Sales 2022 1.42 x
P/E ratio 2021
35.8 x
P/E ratio 2022
20 x
Employees 897
Yield 2021
1.44%
Yield 2022
0.72%
Free-Float 56.74%
More Fundamentals * Assessed data
Dynamic Chart
Zhe Jiang Dayang Biotech Group Co., Ltd. Proposes Final Cash Dividend for 2023 CI
Tranche Update on Zhe Jiang Dayang Biotech Group Co., Ltd.'s Equity Buyback Plan announced on February 6, 2024. CI
Zhe Jiang Dayang Biotech Group Co., Ltd. announces an Equity Buyback for CNY 84 million worth of its shares. CI
Zhe Jiang Dayang Biotech Group Co., Ltd. authorizes a Buyback Plan. CI
Zhejiang Dayang Biotech Group Co., Ltd. Approves Interim Cash Dividend for the Year 2023, Payable on November 14, 2023 CI
Certain A Shares of Zhejiang Dayang Biology Technology Co.,Ltd. are subject to a Lock-Up Agreement Ending on 27-OCT-2023. CI
Zhejiang Dayang Biotech Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Zhejiang Dayang Biotech Group Co., Ltd. Approves Interim Cash Dividend for the Year 2023 CI
Zhejiang Dayang Biotech Group Co., Ltd. Announces the Profit Distribution Proposal for the First Half of 2023 CI
Zhejiang Dayang Biotech Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Fujian Shunyue Technology Co., Ltd. announced that it expects to receive CNY 96.672753 million in funding from Zhe Jiang Dayang Biotech Group Co., Ltd. CI
Zhejiang Dayang Biology Technology Co.,Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date Is 29 June 2023 CI
Dayang Biotech Vice Chairman Dies of Illness MT
Zhejiang Dayang Biology Technology Co.,Ltd. Approves Cash Dividend for the Year 2022 CI
Zhejiang Dayang Biology Technology Co.,Ltd. Proposes Cash Profit Distribution for 2022 CI
More news
1 day+0.71%
1 week+13.51%
Current month-2.38%
1 month-2.38%
3 months-8.88%
6 months-16.38%
Current year-24.01%
More quotes
1 week
16.65
Extreme 16.65
19.00
1 month
15.26
Extreme 15.26
19.79
Current year
11.91
Extreme 11.91
24.79
1 year
11.91
Extreme 11.91
25.94
3 years
11.91
Extreme 11.91
36.79
5 years
11.91
Extreme 11.91
44.64
10 years
11.91
Extreme 11.91
44.64
More quotes
Managers TitleAgeSince
Chief Executive Officer 72 75-12-31
Director of Finance/CFO 46 00-08-31
Chief Tech/Sci/R&D Officer 50 92-08-31
Members of the board TitleAgeSince
Director/Board Member 61 21-12-12
Chief Executive Officer 72 75-12-31
Director/Board Member 64 78-09-30
More insiders
Date Price Change Volume
24-04-30 18.48 +0.71% 3,023,914
24-04-29 18.35 +3.91% 1,888,090
24-04-26 17.66 -0.51% 1,639,940
24-04-25 17.75 +3.38% 1,729,360
24-04-24 17.17 +3.12% 1,186,400

End-of-day quote Shenzhen S.E., April 29, 2024

More quotes
Zhejiang Dayang Biotech Group Co Ltd is a China-based company mainly engaged in the production and sales of chemical raw materials such as inorganic salts and veterinary raw materials. The Company's main products include potassium carbonate, potassium bicarbonate, amproline hydrochloride, 2-chloro-6-fluorobenzaldehyde, etc. Its products are used in food, pesticide, fertilizer, medicine and glass fields. The Company conducts its businesses within the Chinese market and to overseas markets.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 003017 Stock